N4 Pharma PLC (LON:N4P)‘s stock had its “speculative buy” rating restated by equities research analysts at Beaufort Securities in a research report issued on Thursday.
N4 Pharma PLC (N4P) opened at 6.25 on Thursday. The company’s market capitalization is GBX 4.67 million. The firm has a 50-day moving average of GBX 8.52 and a 200-day moving average of GBX 6.54. N4 Pharma PLC has a 52 week low of GBX 1.20 and a 52 week high of GBX 12.50.
N4 Pharma PLC Company Profile
N4 Pharma Plc, formerly Onzima Ventures plc, is a United Kingdom-based specialist pharmaceutical company. The Company is engaged in reformulating existing drugs and vaccines to improve their performance. It operates in two divisions: generic and vaccines. Its generics division includes Sildenafil, Sartans, Aprepitant and Single dose Hepatitis B.
Receive News & Ratings for N4 Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for N4 Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.
